Surprising result! A thyroid hormone receptor β (THR-β) agonist appears effective in improving #NASH .

Decreased THR-β activation promotes NASH by 'reducing mitochondrial function and β-oxidation of fatty acids' which ultimately leads to fibrosis.

nejm.org/doi/full/10.10…

MODERN is now activated. Please help define a precision-based approach to adjuvant therapy in bladder cancer. Bladder Cancer Advocacy Network Uromigos Alliance for Clinical Trials in Oncology Alan Tan Stephanie Berg Jonathan Rosenberg MD Shilpa Gupta Andrea Apolo, M.D. SWOG Cancer Research Network ECOG-ACRIN Cancer Research Group Petros Grivas Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO DrTylerStewart

Best of ESMO 2023. Prostate Cancer Update. Glad for this opportunity to review the data presented at ESMO. totalhealthoncology.com/post/esmo-east…

Interesting The ASCO Post interview with WCM Englander Institute for Precision Medicine's Director of #BladderCancer Research Dr. Bishoy Faltas (@FaltasLab) on 'Upper Tract Urothelial Carcinoma: How Biology Shapes Therapy.'

ascopost.com/videos/24th-su…

Bruno Bastos MD of Miami Cancer Institute Research discussed how TPST-1120 can help address limited treatment options for patients with advanced #RCC beyond immunotherapy and anti-VEGF TKIs. #GU24

targetedonc.com/view/beyond-im…

Summary of clinical trials in advanced non-clear cell RCC #GU24 . The studies are small & pathology mixed ‘the moons of Jupiter’. The focus on PD1 & VEGF was not driven by the biology. Large randomised trials such as SAMETA exploring MET in selected papillary seems like progress.

Congratulations to Dr. Braghiroli, recipient of the Kalman Bass Endowed Chair in Skin Cancer Baptist Health Baptist Health Cancer Care

Updated table of IO combos (ITT population) in front line mRCC after #ASCOGU24 . Has anything changed for you based on these data?

We're thrilled to announce the exceptional achievement of our #MiamiCancerInstitute physician-researchers and #genitourinary medical oncologists, Dr. Rohan Garje, MD + Dr. Bruno Bastos MD who were selected to present their #research at ASCO #GU24 .

Dr. Bishoy M. Faltas presenting at #GU24 on using multimodal deep learning with S1314 to predict #bladdercancer clinical outcomes - utilizing histopathology, cell types and gene expression.

Thanks UroToday.com for highlighting our work presented ASCO #GU24

I can say I understand AI better because of the more-than-stellar presentation of Dr. Bishoy M. Faltas #GU24

A quick summary of our retrospective analysis of HER2 in bladder cancer from from our group Gopa Iyer Neil Shah Hikmat Al Ahmadie Memorial Sloan Kettering Cancer Center

Presented at ASCO #GU24 from VJ Oncology

Correlations between HER2 and PD-L1 expression in bladder ca... youtu.be/ziEnuvdnguk?si…

ASCO #GU24 #Discussant : Adjuvant treatment for #RCC – Strategies on how to optimize patient selection for the new Standard of Care. Presentation by Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr. Written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3vPHnrc

Had a lot of fun presenting our work ASCO #GU24 featuring a deep learning model 🔗fusing outputs of 3 neural networks trained on pathology images 🔬+ gene expression 🧬+ spatial cell data from patients with bladder cancer to predict clinical trial responses to chemotherapy.

WATCH: Bruno Bastos MD discusses findings from a study which assessed the pharmacodynamic and radiographic changes among patients with #RCC who were treated with the combination of nivolumab and TPST-1120. Baptist Health Cancer Care

targetedonc.com/view/ppar--inh…

Our study showed association between fatty acid genomic and pharmacodynamic modulation with clinical response in patients with ccRCC treated with the PPAR alpha antagonist TPST-1120 ASCO #GU24 #RCC #Cancer